NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

WGS

GeneDx Holdings Corp

Apr 30 • 01:21PM ET

71.57

Dollar change -45.40
Percentage change -38.81	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH QDEL NTRA EXAS MYGN TWST CDNA CRSP VERV

| Held by: VTI IWM VXF IWN SCHA VTWO FBCG VHT FESM FYX

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.99	Insider Own	12.60%	Shs Outstand	28.02M	Perf Week	-32.28%
Market Cap	2.04B	Forward P/E	37.32	EPS next Y	1.92	Insider Trans	-27.95%	Shs Float	24.94M	Perf Month	-19.19%
Income	-52.29M	PEG	-	EPS next Q	0.15	Inst Own	84.63%	Short Float	13.04%	Perf Quarter	-5.42%
Sales	305.45M	P/S	6.69	EPS this Y	242.01%	Inst Trans	24.32%	Short Ratio	3.11	Perf Half Y	21.68%
Book/sh	8.75	P/B	8.18	EPS next Y	120.65%	ROA	-11.14%	Short Interest	3.25M	Perf Year	545.94%
Cash/sh	4.95	P/C	14.46	EPS next 5Y	125.40%	ROE	-22.10%	52W Range	13.90 - 117.75	Perf YTD	-6.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	96.65%	ROI	-14.60%	52W High	-39.22%	Beta	1.95
Dividend TTM	-	Quick Ratio	3.42	Sales past 5Y	16.51%	Gross Margin	57.78%	52W Low	414.89%	ATR (14)	10.96
Dividend Ex-Date	-	Current Ratio	3.61	EPS Y/Y TTM	73.57%	Oper. Margin	-7.03%	RSI (14)	35.93	Volatility	5.42% 8.66%
Employees	1000	Debt/Eq	0.48	Sales Y/Y TTM	50.79%	Profit Margin	-17.12%	Recom	2.00	Target Price	107.83
Option/Short	Yes / Yes	LT Debt/Eq	0.46	EPS Q/Q	119.56%	Payout	-	Rel Volume	8.07	Prev Close	116.97
Sales Surprise	9.63%	EPS Surprise	365.65%	Sales Q/Q	66.57%	Earnings	Apr 30 BMO	Avg Volume	1.05M	Price	71.57
SMA20	-25.23%	SMA50	-25.62%	SMA200	5.51%	Trades		Volume	5,177,761	Change	-38.81%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$34
Jul-10-24	Initiated	Craig Hallum	Buy	$43
Jun-03-24	Resumed	Jefferies	Hold	$21

Today 01:15PM	GeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call Transcript (Seeking Alpha) -38.81%
12:28PM	Why GeneDx Holdings Stock Is Plunging Today (Motley Fool)
08:53AM	IBD 50's GeneDx, Down 39%, Was 'Priced For Perfection.' Here's What It Missed. (Investor's Business Daily)
08:53AM	IBD 50 Stock GeneDx Hammered Despite Earnings Beat-And-Raise (Investor's Business Daily)
07:45AM	GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates (Zacks)
06:30AM	Loading…
06:30AM	GeneDx Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
Apr-29-25 12:00PM	GENEDX HOLDINGS (WGS) Upgraded to Buy: Here's Why (Zacks)
Apr-28-25 11:13AM	GeneDx: Strengthening Leadership In Genomic Diagnostics (Seeking Alpha)
Apr-25-25 10:54AM	Meta Stock Struggles, Tries To Bottom Ahead Of Q1 Results; These Growth Stocks Look Much Stronger (Investor's Business Daily)
Apr-23-25 05:46PM	GeneDx Holdings Corp. (WGS): Among the Best Multibagger Stocks to Buy According to Billionaires (Insider Monkey) +9.08%
Apr-21-25 09:57AM	Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results? (Zacks)
Apr-18-25 08:01AM	GeneDx Holdings Corp. (WGS) Rose on Robust Customer Demand (Insider Monkey)
Apr-16-25 04:02PM	IBD 50's GeneDx Inks $51 Million AI-Tied Takeover Deal (Investor's Business Daily)
06:00AM	GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale (Business Wire)
Apr-08-25 08:05AM	GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025 (Business Wire)
08:00AM	Loading…
Apr-03-25 08:00AM	GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication (Business Wire) -5.61%
Apr-02-25 09:33AM	Buy 3 Momentum Anomaly Stocks as Markets Rise Despite Tariff Threats (Zacks)
Mar-22-25 05:48PM	Is GeneDx Holdings (WGS) The High Growth Low Debt Stock to Invest in Now? (InsiderMonkey)
Mar-20-25 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.94%
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:00AM	Zacks.com featured highlights DRDGOLD, GeneDx, EverQuote, HCI Group and Alibaba (Zacks) +7.32%
Mar-18-25 07:05AM	Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies (Business Wire)
Mar-13-25 08:30AM	GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting (Business Wire)
08:30AM	GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis (Business Wire)
Mar-07-25 07:00AM	How This Top Small-Cap Growth Fund Wins Big (Investor's Business Daily)
Mar-04-25 08:30AM	GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication (Business Wire)
Feb-24-25 11:00AM	Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols (Business Wire)
Feb-18-25 04:58PM	Top Biotech GeneDx Catapults 48% After Obliterating Earnings Forecasts (Investor's Business Daily) +47.69%
06:00AM	GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025 (Business Wire)
Feb-13-25 08:30AM	GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients (Business Wire) +9.91%
04:05PM	Loading…
Feb-12-25 04:05PM	GeneDx to Participate in 45th Annual TD Cowen Health Care Conference (Business Wire)
Feb-10-25 08:30AM	GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment (Business Wire) +14.46%
Jan-28-25 04:30PM	GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025 (Business Wire) +5.85%
Jan-17-25 04:30PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.02%
Jan-14-25 09:25AM	GeneDx raises Q4 adjusted gross margin view to 68% from 64% (TipRanks) -15.30%
Jan-13-25 08:30AM	GeneDx Announces Preliminary 2024 Financial Results (Business Wire)
Jan-10-25 03:24PM	Outlook For These Biotechs Brightens As FDA Ushers In New Rules For Sector (Investor's Business Daily) -7.45%
Jan-09-25 08:30AM	GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers (Business Wire)
Jan-08-25 08:30AM	GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients (Business Wire)
Jan-06-25 04:04PM	IBD 50's GeneDx Adds To Nearly 2,700% Sprint With FDA Guide On AI (Investor's Business Daily) +13.23% +8.29%
01:39PM	IBD 50's GeneDx Surges On FDA Recommendations For AI Device Development (Investor's Business Daily)
Jan-04-25 08:00AM	Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly (Investor's Business Daily)
Jan-02-25 04:01PM	GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer (Business Wire)
Dec-30-24 01:00PM	How IBD Stock Of The Day GeneDx Landed On The IBD 50 And Notched A 2,500% Gain (Investor's Business Daily)
Dec-16-24 04:05PM	GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +6.72%
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Nov-25-24 01:26PM	This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win (Investor's Business Daily)
Nov-22-24 04:05PM	GeneDx to Participate in Upcoming Investor Conference (Business Wire) +9.21%
Nov-19-24 08:30AM	GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover (Business Wire)
Nov-18-24 08:30AM	GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary (Business Wire)
Nov-07-24 04:35PM	New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields (Business Wire)
Nov-04-24 04:35PM	GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting (Business Wire)
Oct-29-24 08:00AM	GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) +49.88%
Oct-24-24 11:10AM	Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening (Business Wire) +5.37%
Oct-08-24 08:30AM	GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns (Business Wire)
Oct-03-24 04:05PM	GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 (Business Wire) +5.73%
Sep-27-24 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.34%
Aug-12-24 04:05PM	GeneDx to Participate in Fall Investor Conferences (Business Wire)
Aug-09-24 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-30-24 08:57PM	WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) -10.57% +8.60%
04:05PM	GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
04:05PM	GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients (Business Wire)
Jul-12-24 12:00PM	All You Need to Know About GENEDX HOLDINGS (WGS) Rating Upgrade to Strong Buy (Zacks)
Jul-11-24 04:05PM	GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024 (GlobeNewswire) +9.36%
Jul-06-24 07:00AM	7 Small-Cap Stocks With Massive Potential Returns (InvestorPlace)
Jun-10-24 08:30AM	GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients (GlobeNewswire)
Jun-05-24 07:00AM	GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients (GlobeNewswire) +13.20%
May-22-24 04:05PM	GeneDx to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-24 02:20PM	Hedge Fund and Insider Trading News: Michael Burry, Leon Cooperman, Ray Dalio, Stanley Druckenmiller, Millennium Management, Paulson & Co, Rokos Capital Management, Humacyte Inc (HUMA), GeneDx Holdings Corp. (WGS), and More (Insider Monkey) +13.52%
Apr-30-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +55.18%
Apr-29-24 08:55PM	WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:50PM	GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	GeneDx Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-23-24 08:30AM	GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset (GlobeNewswire) +15.50%
Apr-04-24 04:05PM	GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 (GlobeNewswire) +10.39%
Mar-21-24 09:55AM	Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher (Zacks) +7.87%
Mar-14-24 08:30AM	GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics (GlobeNewswire)
Feb-26-24 04:05PM	GeneDx to Participate in 44th Annual Cowen Health Care Conference (GlobeNewswire)
Feb-21-24 08:33AM	GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2023 Earnings Call Transcript (Insider Monkey) +32.63%
Feb-20-24 04:26PM	GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024 (GlobeNewswire)
Feb-01-24 04:30PM	GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 (GlobeNewswire)
Jan-24-24 04:30PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.98%
Jan-08-24 08:55AM	GeneDx Announces Preliminary 2023 Financial Results (GlobeNewswire) +40.36%
Dec-01-23 08:30AM	GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy (GlobeNewswire)
Nov-28-23 04:05PM	GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +12.80%
Nov-20-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -13.13%
Nov-10-23 09:55AM	Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now (Zacks) -13.61%
Nov-05-23 12:10PM	GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 08:19AM	Q3 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents) -30.34%
Oct-30-23 06:02PM	GeneDx Holdings Corp (WGS) Reports Q3 2023 Financial Results (GuruFocus.com) -8.56%
04:05PM	GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-09-23 04:05PM	GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023 (GlobeNewswire)
Sep-22-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-23 01:01PM	Insider Sell: CEO Katherine Stueland Sells 2,675 Shares of GeneDx Holdings Corp (GuruFocus.com) -5.03%
Sep-11-23 08:00AM	GeneDx Announces Evolution of Executive Leadership Team (GlobeNewswire)
Sep-06-23 08:00AM	GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced (GlobeNewswire)
Aug-21-23 07:00AM	GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine (GlobeNewswire)
Aug-09-23 08:16AM	PacBio (PACB) Inks Research Collaboration for Genome Sequencing (Zacks) -12.63%
07:59AM	Q2 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 08:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kevin Feeley	Officer	Apr 29 '25	Proposed Sale	113.14	388	43,900		Apr 29 09:52 PM
Katherine Stueland	Director	Apr 29 '25	Proposed Sale	113.09	2,154	243,600		Apr 29 09:51 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Apr 14 '25	Proposed Sale	101.04	250,000	25,260,000		Apr 14 08:00 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 09 '25	Option Exercise	32.67	1,246	40,707	17,242	Apr 10 04:12 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 09 '25	Sale	92.18	15,516	1,430,334	1,726	Apr 10 04:12 PM
Stueland Katherine	Chief Executive Officer	Apr 09 '25	Sale	89.62	46,594	4,175,817	1,720	Apr 10 04:11 PM
Feeley Kevin	Officer	Apr 09 '25	Proposed Sale	91.80	14,270	1,310,000		Apr 09 05:36 PM
Stueland Katherine	Officer	Apr 09 '25	Proposed Sale	87.99	46,594	4,100,000		Apr 09 05:10 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 26 '25	Option Exercise	0.00	16,250	0	24,742	Mar 28 04:07 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 26 '25	Sale	95.61	8,746	836,211	15,996	Mar 28 04:07 PM
Stueland Katherine	Chief Executive Officer	Mar 26 '25	Option Exercise	0.00	80,000	0	94,865	Mar 28 04:07 PM
Stueland Katherine	Chief Executive Officer	Mar 26 '25	Sale	95.62	46,551	4,451,084	48,314	Mar 28 04:07 PM
Kevin Feeley	Officer	Mar 26 '25	Proposed Sale	95.61	8,746	836,200		Mar 26 06:36 PM
Katherine Stueland	Director	Mar 26 '25	Proposed Sale	95.62	46,551	4,451,200		Mar 26 06:34 PM
Stueland Katherine	Chief Executive Officer	Mar 16 '25	Option Exercise	0.00	18,750	0	25,424	Mar 17 09:51 PM
Stueland Katherine	Chief Executive Officer	Mar 17 '25	Sale	96.71	10,559	1,021,146	14,865	Mar 17 09:51 PM
Stueland Katherine	Chief Executive Officer	Mar 13 '25	Sale	89.44	1,078	96,420	6,674	Mar 17 09:51 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 17 '25	Sale	96.71	3,749	362,565	8,492	Mar 17 09:50 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 13 '25	Sale	90.05	402	36,202	5,044	Mar 17 09:50 PM
Kevin Feeley	Officer	Mar 17 '25	Proposed Sale	96.72	3,749	362,600		Mar 17 06:46 PM
Katherine Stueland	Director	Mar 17 '25	Proposed Sale	96.70	10,559	1,021,100		Mar 17 06:44 PM
Kevin Feeley	Officer	Mar 13 '25	Proposed Sale	90.05	402	36,200		Mar 13 07:04 PM
Katherine Stueland	Officer	Mar 13 '25	Proposed Sale	89.42	1,078	96,400		Mar 13 07:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 09 '25	Option Exercise	0.00	2,462	0	6,368	Mar 11 05:42 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 10 '25	Sale	94.72	922	87,334	5,446	Mar 11 05:42 PM
Stueland Katherine	Chief Executive Officer	Mar 09 '25	Option Exercise	0.00	6,546	0	10,483	Mar 11 05:40 PM
Stueland Katherine	Chief Executive Officer	Mar 10 '25	Sale	94.73	2,731	258,695	7,752	Mar 11 05:40 PM
Kevin Feeley	Officer	Mar 10 '25	Proposed Sale	94.69	922	87,300		Mar 10 07:44 PM
Katherine Stueland	Officer	Mar 10 '25	Proposed Sale	94.73	2,731	258,700		Mar 10 07:43 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 01 '25	Option Exercise	0.00	717	0	4,167	Mar 04 04:36 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 03 '25	Sale	103.94	261	27,128	3,906	Mar 04 04:36 PM
Kevin Feeley	Officer	Mar 03 '25	Proposed Sale	103.83	261	27,100		Mar 03 06:59 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Feb 24 '25	Proposed Sale	95.83	373,569	35,799,117		Feb 24 08:00 PM
RUCH JOSHUA	Director	Feb 05 '25	Option Exercise	7.89	5,816	45,888	16,799	Feb 07 04:01 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 29 '25	Option Exercise	0.00	753	0	3,225	Jan 31 05:47 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 29 '25	Sale	78.48	275	21,582	2,950	Jan 31 05:47 PM
Stueland Katherine	Chief Executive Officer	Jan 29 '25	Option Exercise	0.00	3,874	0	5,594	Jan 31 05:46 PM
Stueland Katherine	Chief Executive Officer	Jan 29 '25	Sale	78.48	1,657	130,046	3,937	Jan 31 05:46 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Jan 30 '25	Proposed Sale	77.86	1,346,123	104,809,137		Jan 30 08:02 PM
Kevin Feeley	Officer	Jan 29 '25	Proposed Sale	78.55	275	21,600		Jan 29 09:06 PM
Katherine Stueland	Director	Jan 29 '25	Proposed Sale	78.46	1,657	130,000		Jan 29 09:04 PM
RUCH JOSHUA	Director	Jan 17 '25	Option Exercise	7.89	3,000	23,670	10,983	Jan 22 05:08 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 07 '25	Option Exercise	32.67	11,208	366,165	37,978	Jan 10 05:54 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 07 '25	Sale	93.82	35,506	3,331,024	2,472	Jan 10 05:54 PM
Stueland Katherine	Chief Executive Officer	Jan 07 '25	Sale	94.48	51,420	4,858,119	1,720	Jan 10 05:53 PM
Feeley Kevin	Officer	Jan 07 '25	Proposed Sale	94.07	35,506	3,340,000		Jan 07 05:02 PM
Stueland Katherine	Officer	Jan 07 '25	Proposed Sale	93.93	51,420	4,830,000		Jan 07 04:44 PM
Stueland Katherine	Chief Executive Officer	Jan 02 '25	Sale	78.18	18,006	1,407,686	53,140	Jan 06 06:05 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 02 '25	Sale	76.04	1,430	108,737	26,770	Jan 06 06:04 PM
Feeley Kevin	Officer	Jan 02 '25	Proposed Sale	75.52	1,430	108,000		Jan 02 05:03 PM
Stueland Katherine	Officer	Jan 02 '25	Proposed Sale	77.75	18,006	1,400,000		Jan 02 04:31 PM
Stueland Katherine	Chief Executive Officer	Dec 16 '24	Option Exercise	0.00	18,750	0	81,647	Dec 18 06:22 PM
Stueland Katherine	Chief Executive Officer	Dec 16 '24	Sale	76.75	10,501	805,995	71,146	Dec 18 06:22 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 16 '24	Option Exercise	0.00	7,197	0	31,928	Dec 18 06:21 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 16 '24	Sale	76.75	3,728	286,139	28,200	Dec 18 06:21 PM
Kevin Feeley	Officer	Dec 16 '24	Proposed Sale	76.75	3,728	286,139		Dec 16 08:41 PM
Katherine Stueland	Officer	Dec 16 '24	Proposed Sale	76.75	10,501	805,995		Dec 16 08:40 PM
Stueland Katherine	Chief Executive Officer	Dec 09 '24	Option Exercise	0.00	6,547	0	66,558	Dec 11 07:19 PM
Stueland Katherine	Chief Executive Officer	Dec 09 '24	Sale	76.37	3,661	279,598	62,897	Dec 11 07:19 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 09 '24	Option Exercise	0.00	2,462	0	25,868	Dec 11 07:18 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 09 '24	Sale	76.37	1,137	86,836	24,731	Dec 11 07:18 PM
Kevin Feeley	Officer	Dec 09 '24	Proposed Sale	76.37	1,137	86,836		Dec 09 08:06 PM
Katherine Stueland	Director	Dec 09 '24	Proposed Sale	76.37	3,661	279,598		Dec 09 08:05 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 01 '24	Option Exercise	0.00	718	0	23,669	Dec 03 07:21 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Dec 02 '24	Sale	78.39	263	20,617	23,406	Dec 03 07:21 PM
Kevin Feeley	Officer	Dec 02 '24	Proposed Sale	78.39	263	20,617		Dec 02 08:01 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Nov 21 '24	Sale	73.76	12,019	886,568	32,932	Nov 25 06:21 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Nov 22 '24	Sale	76.07	9,981	759,242	22,951	Nov 25 06:21 PM
Ryan Jason	Director	Nov 19 '24	Sale	71.28	31,510	2,246,130	15,490	Nov 21 08:21 PM
Ryan Jason	Director	Nov 20 '24	Sale	69.13	15,490	1,070,749	0	Nov 21 08:21 PM
Feeley Kevin	Officer	Nov 21 '24	Proposed Sale	72.73	22,000	1,600,000		Nov 21 06:14 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Nov 18 '24	Sale	70.78	126,782	8,973,059	2,719,692	Nov 19 08:00 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Nov 15 '24	Sale	69.78	20,359	1,420,663	2,846,474	Nov 19 08:00 PM
Stueland Katherine	Chief Executive Officer	Nov 15 '24	Sale	70.48	23,108	1,628,593	82,318	Nov 19 07:05 PM
Stueland Katherine	Chief Executive Officer	Nov 18 '24	Sale	70.34	22,307	1,569,091	60,011	Nov 19 07:05 PM
Ryan Jason	Officer	Nov 19 '24	Proposed Sale	70.00	47,000	3,290,000		Nov 19 05:10 PM
Stueland Katherine	Officer	Nov 15 '24	Proposed Sale	70.02	45,415	3,180,000		Nov 15 04:58 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Oct 31 '24	Sale	75.00	865,800	64,935,000	2,866,833	Nov 04 05:01 PM
ICAHN SCHOOL OF MEDICINE AT MO	10% Owner	Oct 31 '24	Proposed Sale	81.69	1,012,941	82,747,150		Oct 31 08:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Oct 29 '24	Option Exercise	0.00	753	0	45,225	Oct 31 05:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Oct 29 '24	Sale	66.60	274	18,248	44,951	Oct 31 05:14 PM
Stueland Katherine	Chief Executive Officer	Oct 29 '24	Option Exercise	0.00	3,874	0	107,580	Oct 31 05:13 PM
Stueland Katherine	Chief Executive Officer	Oct 29 '24	Sale	66.60	2,154	143,456	105,426	Oct 31 05:13 PM
Kevin Feeley	Officer	Oct 29 '24	Proposed Sale	66.60	274	18,248		Oct 29 07:45 PM
Katherine Stueland	Officer	Oct 29 '24	Proposed Sale	66.60	2,154	143,456		Oct 29 07:44 PM
OPKO HEALTH, INC.	10% Owner	Sep 17 '24	Proposed Sale	40.88	13,404	547,956		Sep 20 02:56 PM
Stueland Katherine	Chief Executive Officer	Sep 16 '24	Option Exercise	0.00	18,750	0	114,207	Sep 18 04:28 PM
Stueland Katherine	Chief Executive Officer	Sep 16 '24	Sale	37.59	10,501	394,733	103,706	Sep 18 04:28 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 16 '24	Option Exercise	0.00	7,197	0	47,107	Sep 18 04:26 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 16 '24	Sale	37.59	2,635	99,050	44,472	Sep 18 04:26 PM
Kevin Feeley	Officer	Sep 16 '24	Proposed Sale	37.59	2,635	99,050		Sep 16 06:54 PM
Katherine Stueland	Director	Sep 16 '24	Proposed Sale	37.59	10,501	394,733		Sep 16 06:54 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '24	Option Exercise	0.00	2,462	0	40,805	Sep 11 08:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '24	Sale	33.33	895	29,830	39,910	Sep 11 08:14 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '24	Option Exercise	0.00	6,546	0	99,096	Sep 11 08:10 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '24	Sale	33.33	3,639	121,288	95,457	Sep 11 08:10 PM
Kevin Feeley	Officer	Sep 09 '24	Proposed Sale	33.33	895	29,830		Sep 09 09:03 PM
Katherine Stueland	Officer	Sep 09 '24	Proposed Sale	33.33	3,639	121,288		Sep 09 09:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 01 '24	Option Exercise	0.00	717	0	38,605	Sep 04 08:10 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 03 '24	Sale	31.71	262	8,308	38,343	Sep 04 08:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

WGS

GeneDx Holdings Corp

Upgrade your FINVIZ experience